216 related articles for article (PubMed ID: 12171896)
1. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
4. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
5. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
6. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
7. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
8. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
Stephen AE; Masiakos PT; Segev DL; Vacanti JP; Donahoe PK; MacLaughlin DT
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3214-9. PubMed ID: 11248058
[TBL] [Abstract][Full Text] [Related]
9. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
Behringer RR; Cate RL; Froelick GJ; Palmiter RD; Brinster RL
Nature; 1990 May; 345(6271):167-70. PubMed ID: 2336108
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
11. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
12. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
13. Müllerian inhibiting substance inhibits testosterone synthesis in adult rats.
Sriraman V; Niu E; Matias JR; Donahoe PK; MacLaughlin DT; Hardy MP; Lee MM
J Androl; 2001; 22(5):750-8. PubMed ID: 11545286
[TBL] [Abstract][Full Text] [Related]
14. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody to Mullerian inhibiting substance.
Mudgett-Hunter M; Budzik GP; Sullivan M; Donahoe PK
J Immunol; 1982 Mar; 128(3):1327-33. PubMed ID: 6895760
[TBL] [Abstract][Full Text] [Related]
16. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
17. Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance.
Donahoe PK; Krane I; Bogdén AE; Kamagata S; Budzik GP
J Pediatr Surg; 1984 Dec; 19(6):863-9. PubMed ID: 6084056
[TBL] [Abstract][Full Text] [Related]
18. Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.
Donahoe PK; Fuller AF; Scully RE; Guy SR; Budzik GP
Ann Surg; 1981 Oct; 194(4):472-80. PubMed ID: 6895157
[TBL] [Abstract][Full Text] [Related]
19. Mullerian-inhibiting substance secretion is delayed in XX sex-reversed dog embryos.
Meyers-Wallen VN; MacLaughlin D; Palmer V; Donahoe PK
Mol Reprod Dev; 1994 Sep; 39(1):1-7. PubMed ID: 7999353
[TBL] [Abstract][Full Text] [Related]
20. Identification of müllerian inhibiting substance specific binding in human cell lines.
MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
